Clinical Trials Logo

Leishmaniasis, Cutaneous clinical trials

View clinical trials related to Leishmaniasis, Cutaneous.

Filter by:

NCT ID: NCT00257530 Completed - Clinical trials for Cutaneous Leishmaniasis

Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our previous results, we hypothesize that lesions in patients who receive the combined treatment of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and produce less scarring than treatment with pentavalent antimony alone.

NCT ID: NCT00233545 Completed - Clinical trials for Cutaneous Leishmaniasis

Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.

NCT ID: NCT00121862 Completed - Clinical trials for Cutaneous Leishmaniasis

Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.

NCT ID: NCT00121849 Completed - Clinical trials for Cutaneous Leishmaniasis

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Start date: August 2005
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).

NCT ID: NCT00111553 Completed - Clinical trials for Leishmaniasis, Cutaneous

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

Start date: October 2004
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult patients with cutaneous leishmaniasis.

NCT ID: NCT00004755 Completed - Leishmaniasis Clinical Trials

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil

Start date: September 1995
Phase: Phase 2
Study type: Interventional

OBJECTIVE: Compare the efficacy and side effects of allopurinol versus glucantime versus allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.

NCT ID: NCT00001906 Completed - Clinical trials for Cutaneous Leishmaniasis

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

Start date: April 1999
Phase: Phase 1
Study type: Interventional

While vaccination against cutaneous leishmaniasis, a chronic ulcerating protozoan infection of the skin, has been possible for decades using live parasites, the production and storage of live cultures are difficult. Since inoculation occasionally leads to severe infection, most experts now advocate against their use. We have shown excellent protection using a "heat-killed" vaccine that combines autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants in a rhesus macaque model of disease. To assess the safety and immunogenicity of this vaccine in humans, we now propose a rhIL-12 dose escalation Phase I/II trial.